ClinicalTrials.gg
CompletedNCT05917964Updated Sep 11, 2023

A Food Effect Study of LP-168 Tablets in Healthy Subjects

A Phase 1 interventional study of LP-168 tablet in Mantle Cell Lymphoma, sponsored by Guangzhou Lupeng Pharmaceutical Company LTD.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Guangzhou Lupeng Pharmaceutical Company LTD. (part of Lupeng Pharmaceutical Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Enrollment
70th of 91
22 · median 50
Started
2023
with 5 others
Phase 1
16 of 98
6 open now
Registered
60th of 98
by date
Lead sponsor
4 of 98
Guangzhou Lupeng Pharmaceutical Company LTD.

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 70th largest by enrollment of the 91 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 in phase 1, and was the 60th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

This is a randomized, two-period, two-sequence two-treatment crossover design food effect study to evaluate the pharmacokinetic profile of LP-168 tablets in healthy subjects after single oral administration under fasted and fed conditions

Read the detailed description

A total of 22 subjects from Cohort A and Cohort B, with a single sex ratio of not less than 1/3, will be included in this study. Each subject will undergo two cycles of self-crossover dosing, respectively. 4 days of PK sample collection and safety observation period will be conducted after the first dose for the first cycle, followed by the 4-day second cycle of PK sample collection and safety observation. The washout period between the 2 doses will be 7 days.

Subjects who voluntarily participate in the study and complete the informed consent process will be randomly assigned to the fasted-fed group (Cohort A) or the fed-fasted group (Cohort B) in a 1:1 ratio after completion of all screening visit examinations and after the investigator determines that all inclusion criteria are met and all exclusion criteria are not met. Cohort A was administered once in Cycle 1 Day1 under fasted condition and once in Cycle 2 Day1 (i.e., Day8 after Cycle 1 administration) under fed condition for a total of 2 doses; cohort B was administered once in Cycle 1 Day 1 under fed condition and once in Cycle 2 Day 1 (i.e., D8 after Cycle 1 administration) under fasted conditions for a total of 2 doses, both at a dose of 150 mg of LP-168 tablets.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer
  • Subjects (including partners) are willing to take effective measures during study and within 3 months after last dose
  • Male and female healthy subjects aged 18 to 55 years old
  • Male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg
  • Subjects able to understand and comply with study requirements
  • Willing to sign the

Exclusion criteria

Exclusion Criteria:

  • Abnormal vital signs, physical examination or laboratory tests with clinical significance
  • Abnormal or echocardiography with clinical significance
  • virus, virus, and syphilis test positive. COVID-19 DNA positive.
  • Subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug
  • Subjects who have consumed diets that may alter the activity of liver metabolic enzymes within 7 days before administration the study drug
  • Subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug
  • Subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion
  • Female subjects are breastfeeding or pregnant
  • Subjects who have a history of drug/ alcohol/ tobacco abuse
  • Subjects who have had a blood donation or massive blood loss within three months before screening; or had surgery within six months before screening
  • Subjects who have participated in other clinical trial within three months before screening
  • Subjects have special dietary requirements or cannot tolerate a standard meal
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Cohort A (fasted-fed)

    Cohort A was administered once in Cycle 1 Day1 under fasted condition and once in Cycle 2 Day1 (i.e., Day8 after Cycle 1 administration) under fed condition for a total of 2 doses.

    Drug: LP-168 tablet

  • Experimental
    Cohort B (fed-fasted)

    Cohort B was administered once in Cycle 1 Day 1 under fed condition and once in Cycle 2 Day 1 (i.e., D8 after Cycle 1 administration) under fasted conditions for a total of 2 doses.

    Drug: LP-168 tablet

Interventions

  • LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration

    Also known as: NWP-775

06

What researchers measure

Primary outcomes

  1. PK Parameter AUC0-t

    PK As Assessed By Area Under The Plasma Concentration Time Curve From Time 0 To The Time of The Last Quantifiable Concentration Of LP-168

    Time frame: Up to 72 hours post last dose

  2. PK Parameter AUC0-∞

    PK As Assessed By Area Under The Plasma Concentration Time Curve From Time 0 To The Time of Intersection of the extrapolated concentration-time curve and the time-axis Of LP-168 PK curve

    Time frame: Up to 72 hours post last dose

  3. PK Parameter Cmax

    Pharmacokinetics (PK) As Assessed By Maximum Observed Plasma Concentration of LP-168

    Time frame: Up to 72 hours post last dose

  4. PK Parameter Tmax

    PK As Assessed By Time To Maximum Observed Plasma Concentration of LP-168

    Time frame: Up to 72 hours post last dose

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events as determined by CTCAE v5.0

    Time frame: From the first dose of the study drug to 4 days after last dose]

  2. Severity of Treatment Emergent Adverse Events as determined by CTCAE v5.0

    Time frame: From the first dose of the study drug to 4 days after last dose]

07

Study locations

1 site
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2023, 2 months.

Of 55 industry-sponsored phase 1 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 2 months is below that.

Counting every sponsor, half of 128 studies reached it within 61 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jun 26, 2023
StartActual
Jun 21, 2023
Primary completionActual
Aug 21, 2023
CompletionActual
Aug 21, 2023
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917964
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jun 21, 2023
Primary completion
Aug 21, 2023
Completion
Aug 21, 2023
Last update
Sep 11, 2023

Study contacts

Honggang Lou, MS
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion